Dexrazoxane improves cardiac autonomic function in epirubicin-treated breast cancer patients with type 2 diabetes.

Abstract

OBJECTIVE:

The study objective was to investigate the protective effects of dexrazoxane (DRZ) on the cardiac autonomic nervous system (ANS) activity in anthracycline-treated breast cancer patients with diabetes.

METHODS:

A total of 110 early stage breast cancer patients with type 2 diabetes were divided randomly into 2 even groups: chemotherapy alone (Chemo) and chemotherapy + DRZ (Chemo + DRZ). All patients underwent adjuvant chemotherapy (80 mg/m epirubicin and 500 mg/m cyclophosphamide) for a total of 6 cycles with 21 days/cycle. The Chemo + DRZ group patients were treated intravenously with 800 mg/m DRZ 30 minutes prior to the administration of epirubicin, while the Chemo group patients were given saline. The cardiac ANS function was evaluated for each patient before and after 6 cycles of chemotherapy by resting heart rate (RHR) and heart rate variability (HRV), which was evaluated by both time and frequency domains.

RESULTS:

Before and after chemotherapy, patients in both groups showed significant decreases in HRV indices and increases in RHR and the low-frequency/high-frequency ratio. There were no significant differences between Chemo and Chemo + DRZ groups in terms of RHR and HRV indices before chemotherapy; however, after chemotherapy, patients in the Chemo group had a higher average RHR and lower HRV indices compared with patients in the Chemo + DRZ group.

CONCLUSION:

DRZ protects the cardiac ANS in epirubicin-treated early stage breast cancer patients with diabetes.

• Authors: Fangyi Sun, Jing Shi, Cuizhi Geng
• Journal: Medicine (Medicine (Baltimore)) Vol. 95 Issue 44 Pg. e5228 (Nov 2016) ISSN: 1536-5964 [Electronic] United States
• PMID: 27858873 (Publication Type: Journal Article, Randomized Controlled Trial)

Chemical References

• Antineoplastic Agents
• Dexrazoxane
• Epirubicin

Topics

• Antineoplastic Agents (pharmacology, therapeutic use)
• Autonomic Nervous System (drug effects, physiopathology)
• Breast Neoplasms (complications, drug therapy)
• Dexrazoxane (pharmacology, therapeutic use)
• Diabetes Mellitus, Type 2 (complications)
• Epirubicin (therapeutic use)
• Female
• Heart (drug effects, innervation, physiopathology)
• Humans
• Middle Aged
• Prospective Studies